Mark van Duin

6.1k total citations · 1 hit paper
71 papers, 3.3k citations indexed

About

Mark van Duin is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Mark van Duin has authored 71 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Hematology, 34 papers in Molecular Biology and 31 papers in Oncology. Recurrent topics in Mark van Duin's work include Multiple Myeloma Research and Treatments (56 papers), Protein Degradation and Inhibitors (24 papers) and Ubiquitin and proteasome pathways (11 papers). Mark van Duin is often cited by papers focused on Multiple Myeloma Research and Treatments (56 papers), Protein Degradation and Inhibitors (24 papers) and Ubiquitin and proteasome pathways (11 papers). Mark van Duin collaborates with scholars based in Netherlands, United States and United Kingdom. Mark van Duin's co-authors include Pieter Sonneveld, Kenneth C. Anderson, Francesca Gay, Shaji Kumar, Robert A. Kyle, S. Vincent Rajkumar, María‐Victoria Mateos, Bronno van der Holt, Hartmut Goldschmidt and Annemiek Broyl and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Immunology.

In The Last Decade

Mark van Duin

65 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multiple myeloma

2017 755 citations Shaji Kumar, S. Vincent Rajkumar et al. Nature Reviews Disease Primers profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark van Duin Netherlands	24	1.9k	1.8k	1.4k	507	445	71	3.3k
Geoffrey L. Uy United States	32	1.6k 0.9×	2.9k 1.6×	1.5k 1.1×	236 0.5×	900 2.0×	214	4.6k
Andreas Petzer Austria	26	977 0.5×	1.8k 1.0×	946 0.7×	171 0.3×	879 2.0×	111	3.3k
Elizabeth Hyjek United States	29	1.1k 0.6×	482 0.3×	1.8k 1.3×	544 1.1×	799 1.8×	68	3.6k
Johanna Olweus Norway	26	1.3k 0.7×	696 0.4×	1.5k 1.1×	243 0.5×	1.8k 4.0×	61	3.9k
Michael H. Tomasson United States	32	1.6k 0.9×	1.8k 1.0×	1.3k 0.9×	105 0.2×	486 1.1×	116	3.5k
Maria Antonia Frassanito Italy	30	1.3k 0.7×	1.0k 0.6×	738 0.5×	184 0.4×	723 1.6×	68	2.5k
Scott Ely United States	28	1.3k 0.7×	872 0.5×	1.6k 1.2×	309 0.6×	674 1.5×	89	3.4k
William C. Manning United States	22	1.3k 0.7×	684 0.4×	606 0.4×	575 1.1×	451 1.0×	27	3.0k
Yazan Alsayed United States	29	2.2k 1.2×	1.9k 1.1×	1.5k 1.1×	102 0.2×	529 1.2×	61	3.1k
Jacalyn Rosenblatt United States	31	1.5k 0.8×	1.3k 0.7×	1.7k 1.3×	110 0.2×	1.2k 2.8×	142	3.5k

Countries citing papers authored by Mark van Duin

Since Specialization

Citations

This map shows the geographic impact of Mark van Duin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark van Duin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark van Duin more than expected).

Fields of papers citing papers by Mark van Duin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark van Duin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark van Duin. The network helps show where Mark van Duin may publish in the future.

Co-authorship network of co-authors of Mark van Duin

This figure shows the co-authorship network connecting the top 25 collaborators of Mark van Duin. A scholar is included among the top collaborators of Mark van Duin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark van Duin. Mark van Duin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bruinink, Davine Hofste op, Rowan Kuiper, Mark van Duin, et al.. (2022). Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. Journal of Clinical Oncology. 40(27). 3132–3150. 16 indexed citations

Alberge, Jean-Baptiste, Françoise Kraeber‐Bodéré, Bastien Jamet, et al.. (2022). Molecular Signature of ¹⁸F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study. Journal of Nuclear Medicine. 63(7). 1008–1013. 10 indexed citations

Mutsaers, Pim, Hayri E. Balcıoğlu, Rowan Kuiper, et al.. (2021). V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma. Cancers. 13(9). 2219–2219. 12 indexed citations

Jong, Madelon M.E. de, Zoltán Kellermayer, Natalie Papazian, et al.. (2021). The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nature Immunology. 22(6). 769–780. 128 indexed citations

Verkleij, Christie P.M., Marloes E.C. Broekmans, Mark van Duin, et al.. (2021). Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Advances. 5(8). 2196–2215. 117 indexed citations

Went, Molly, Alex J. Cornish, Philip Law, et al.. (2020). Search for multiple myeloma risk factors using Mendelian randomization. Blood Advances. 4(10). 2172–2179. 26 indexed citations

Bruinink, Davine Hofste op, Vincent van der Velden, Mark van Duin, et al.. (2017). The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow. Blood. 130. 4368–4368.

Wester, Ruth, King H. Lam, Mark van Duin, et al.. (2017). Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Included in the HOVON-87/Nmsg-18 Trial May be Associated with Longer PFS and OS. Blood. 130. 3052–3052. 1 indexed citations

Kumar, Shaji, S. Vincent Rajkumar, Robert A. Kyle, et al.. (2017). Multiple myeloma. Nature Reviews Disease Primers. 3(1). 17046–17046. 755 indexed citations breakdown →

10.

Nijhof, Inger S., Tineke Casneuf, Berris van Kessel, et al.. (2016). CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 128(7). 959–970. 275 indexed citations

11.

Wu, Shijie, Ruth M. Pfeiffer, Inhye E. Ahn, et al.. (2016). Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non- MMSET Myeloma Patients. Clinical Cancer Research. 22(16). 4039–4044. 12 indexed citations

12.

Magrangeas, Florence, Rowan Kuiper, Hervé Avet‐Loiseau, et al.. (2016). A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. Clinical Cancer Research. 22(17). 4350–4355. 30 indexed citations

13.

Kuiper, Rowan, Mark van Duin, Martin H. van Vliet, et al.. (2015). Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood. 126(17). 1996–2004. 77 indexed citations

14.

Kuiper, Rowan, Annemiek Broyl, Yvonne de Knegt, et al.. (2012). A gene expression signature for high-risk multiple myeloma. Leukemia. 26(11). 2406–2413. 198 indexed citations

15.

Duin, Mark van, Annemiek Broyl, Yvonne de Knegt, et al.. (2011). Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica. 96(11). 1662–1669. 52 indexed citations

16.

Broyl, Annemiek, Sophie L. Corthals, Joost L.M. Jongen, et al.. (2010). Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. The Lancet Oncology. 11(11). 1057–1065. 173 indexed citations

17.

Hameetman, Liesbeth, Károly Szuhai, Arzu Yavaş, et al.. (2007). The Role of EXT1 in Nonhereditary Osteochondroma: Identification of Homozygous Deletions. JNCI Journal of the National Cancer Institute. 99(5). 396–406. 77 indexed citations

18.

Duin, Mark van, Ronald van Marion, Kees J. Vissers, et al.. (2005). High‐resolution array comparative genomic hybridization of chromosome arm 8q: Evaluation of genetic progression markers for prostate cancer. Genes Chromosomes and Cancer. 44(4). 438–449. 78 indexed citations

19.

Duin, Mark van, Ronald van Marion, J. E. Vivienne Watson, et al.. (2004). Construction and application of a full‐coverage, high‐resolution, human chromosome 8q genomic microarray for comparative genomic hybridization. Cytometry Part A. 63A(1). 10–19. 16 indexed citations

20.

Duin, Mark van, Renske D.M. Steenbergen, Jillian de Wilde, et al.. (2003). Telomerase activity in high‐grade cervical lesions is associated with allelic imbalance at 6Q14–22. International Journal of Cancer. 105(5). 577–582. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact